-
Long-range recurrence of gliomas is associated with the development of the lower part of the brain and CD133
Time of Update: 2020-12-30
CD133 expression combined with tumor MRI characteristics to predict long-range recurrence rates.
The study showed that combined with GBM's CD133 expression level and mri imaging to show a comprehensive analysis of tumor-tired regions, it helped to predict GBM's long-range recurrence.
-
"Pharmaceutical Express" K drug combination therapy by the FDA priority review of Bedane Shatini...
Time of Update: 2020-12-30
(Sina Pharmaceutical News) EU CHMP recommends approval of Sanofi Pliavix combined aspirin to treat certain types of stroke Recently, Sanofi announced that the European Medicines Agency CHMP has issued a positive review recommending approval of Plavix (Polive) for a new adaptation: for the treatment of high-risk transient ischemic attack or mild ischemic stroke in adult patients.
-
The new purification method is expected to reduce the manufacturing costs and toxic side effects of CAR-T cells
Time of Update: 2020-12-30
Elsemary's study could benefit patients significantly by reducing manufacturing costs and common side effects associated with CAR-T cell therapy.
-
Research and development daily Gilead Tecartus treatment set of cell lymphoma by the European has...
Time of Update: 2020-12-30
Phase III clinical reached a double major endpoint; FDA approved GSK's Benlysta as the first lupus nephritis therapy; Yangzijiang Pharmaceutical Group iodized saline injection two supplementary applications were approved; target drug Devimistat approved treatment of acute myeloid leukemia mitigation rate of nearly half ...
-
First immunotherapy for esophageal cancer (ESCC)! Best-in-the-hundred Opdivo approved by the European Union: second-line treatment significantly extends survival!
Time of Update: 2020-12-29
November 27, 2020 // -- BMS recently announced that the European Commission (EC) has approved the anti-PD-1 therapy Opdivo (Eu Divo, generic name: nivolumab, Navuliyu monomatics) A new adaptive condition used to treat adult patients with non-excisive, advanced, relapsed or metastatic esophageal squamous cell carcinoma (ESCC) who had previously underwent a combination of fluorine and platinum-based chemotherapy.
-
PNAS: New cancer immunotherapy is available! The scavenger's subject MARCO, which targets tumor-related macrophages, activates tumor cell lethality in NK cells
Time of Update: 2020-12-29
"In our study, we developed a new type of immunotherapy: specific antibodies activate macrophages, allowing them to support the immune system and kill cancer cells," said Mikael Karlsson, co-author of the paper and professor in the Department of Microbiology, Oncology and Cell Biology at the Karolinska Institute.
-
New advances in antibody therapy for a variety of diseases!
Time of Update: 2020-12-29
doi:10.1073/pnas.20120731117 Recently, an article published in the international magazine Proceedings of the National Academy of Sciences entitled "Antibody-mediated activation of the FGFR1/Klotho" Scientists from Louisiana State University's Pennington Biomedical Research Center and others have found that an experimental antibody drug that targets one of the body's key metabolic regulators may help obese people lose weight in the short term, according to a study by the beta complex corrects metabolic and research.
-
The new generation of cancer immunotherapy ISAC is here: the tumor is completely regressed, clinical trials are in progress
Time of Update: 2020-12-29
in a new study published December 7 in Nature Cancer, researchers from Bolt Biotherapeutics and Stanford University School of Medicine developed an immunostature antibody concedes (ISAC) that combines the accuracy of antibody-targeted tumors with the lethal potential of congenital and adaptive immune systems into a single drug, enabling complete tumor recedation and long-lasting anti-tumor immunity in a variety of tumor models.
-
Scientists have made new progress in the field of cancer metastasis!
Time of Update: 2020-12-29
File photo: Wikipedia 1 Nat Cancer: Scientists find special genetic markers that promote prostate cancer metastasis or are expected to help develop new individualized anticancer therapies doi:10.1038/s43018-020 In a study published in the international journal Nature Cancer, scientists from Rutgers University and other institutions in the United States found that genetic markers in the human body may be able to promote metastatic prostate cancer through synergy.
-
Muscle-immersive urethroma (MIUC) immunotherapy! Roche Tecentriq shows strong results in ctDNA-positive patients!
Time of Update: 2020-12-28
December 11, 2020 // -- Roche recently presented the anti-PD-L1 therapy Tecentriq at the European Society of Oncology's Online Conference on Immuno-Oncology (ESMO IO) Common name: atezolizumab, atilijudium monoanti) as an auxiliary (postoperative) single-drug therapy to treat muscle-immersive urethrial skin cancer (MIUC) Phase III IMvigor010 study of exploratory results.
-
Head and neck cancer has ushered in a new breakthrough in treatment that has not been expected in a decade
Time of Update: 2020-12-28
On December 11th, the official website of China's State Drug Administration (NMPA) showed that the Merca East PD-1 inhibitor Paboliju monoanti (commodity name: Corida) had been approved for use in assessing tumor expression PD through fully validated testing -L1 (comprehensive positive score (CPS)≥20) metastatic or non-removable relapsed head and neck squamous cell carcinoma (HNSCC) patients first-line treatment, became the first immune first-line treatment of head and neck squamous cancer.
-
Cell: New target for cancer immunotherapy - PHD3
Time of Update: 2020-12-27
, professor of cell biology who led the study, said: "Putting the same tumors in an obese and non-obese environment reveals that cancer cells respond to a high-fat diet to change their metabolism.
-
Immunotherapy significantly improved survival rates in patients with head and neck squamous cancer
Time of Update: 2020-12-27
This approval is based on the total lifetime data from the keyNOTE-048 study of a large-scale Phase III clinical trial worldwide, which aims to assess the efficacy and safety of patients with relapsed or metastatic head and neck squamous cell carcinoma treated with Paboliju monodrative or combined chemotherapy.
-
The effect of GBM molecular division and maximum excision of fortified or non-enhanced lesions on patient prognosis
Time of Update: 2020-12-27
3 groups of 212 patients, age ≤65 years old, postoperative residual NCE lesions>5.4mL, IDH-wt patients treated with thymosamine, the prognosis was better than 2 groups, the middle OS was 16.5 months (95% CI, 14.7-18.3).
-
Bladder cancer is heavy! EU CHMP recommends approval of Merck/Pfizer immunotherapy Bavencio for first-line maintenance therapy: will change clinical practice!
Time of Update: 2020-12-27
14, 2020 // -- Merck KGaA and partner Pfizer have jointly announced that the European Commission (EC) has released a A positive review recommended approval of the anti-PD-L1 therapy Bavencio (avelumab
-
Nat Commun: Inhibits special immunomodulation signaling path pathps in breast cancer or is expected to promote the body's efficient anti-tumor immune response
Time of Update: 2020-12-26
In a recent study published in the international journal Nature Communications, scientists from institutions such as Spain's National Cancer Research Centre found that RANK signaling paths may be a key candidate to help regulate the immune response in breast tumors; : CC0 Public Domain researchers say inhibiting rank proteins may promote the recruitment of immune cells in mouse models and body tumors in breast cancer patients.
-
December 11, 2020 Science Journal Essence
Time of Update: 2020-12-26
17 December 2020 / / --- This week a new issue of Science (December 11, 2020) was published. Let the little editor come with us. images from the Journal of Science. 1.Science: Revealing the developme
-
The results of the clinical study on the treatment of advanced lung squamous cancer of yew alcohol lipids were published
Time of Update: 2020-12-26
Lung cancer has the highest incidence and mortality rate of malignant tumors in the world, and as one of the common histological types of non-small cell lung cancer (NSCLC), the treatment of advanced
-
Tumor immunotherapy upgrade! AstraZeneia Imfinzi's new dosing scheme (1500mg once every 4 weeks) is approved in the EU!
Time of Update: 2020-12-26
December 16, 2020 // -- AstraZeneca recently announced that the European Medicines Agency (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued an active review recommending approval of
-
Low-grade glioma in children
Time of Update: 2020-12-26
In-depth understanding of the molecular and genetic characteristics of glioma in children, to further improve the classification and treatment of tumors, such as the identification of the main cause of glioma in children is the silk rift active protein kinase (MAPK) signaling path path of genetic mutations, braF gene can be used as a therapeutic target.
